## **Prior Authorization**

## AETNA BETTER HEALTH ILLINOIS (MEDICAID)

Actimmune (Medicaid)

This fax machine is located in a secure location as required by HIPAA regulations.

Complete/review information, sign and date. Fax signed forms to Aetna Better Health Illinois at 1-855-684-5250.

When conditions are met, we will authorize the coverage of Actimmune (Medicaid).

Please note that all authorization requests will be reviewed as the AB rated generic (when available) unless states otherwise.

Drug Name (please circle)			
ACTIMMUNE (interferon gamma-1	b)		
Other, Please specify:			
Quantity	Frequency	Strength _	
Route of Administration	Expected Length of therapy		
Patient Information			
Patient Name:			
Patient ID:			
Patient Group No.:			
Patient DOB:			
Patient Phone:			
Prescribing Physician			
Physician Name:			
Specialty:	NPI Number:	-	
Physician Fax:	Physician Phone:		
Physician Address:	City, State, Zip:		
Diagnosis:	ICD Code:		
Please circle the appropriate answ			
area (BSA) is less than of the prescribed dose doe Body surface area (BSA	ne of the following? A) Body surface or equal to 0.5 meters squared AND is not exceed 1.5 mcg per kg, or B) is greater than 0.5 meters squared is does not exceed 50 mcg per meter	Y	N
Please provide patient's	BSA, weight, and prescribed dose:		
[If no, no further question	 ns.1		
•	•		
<ol><li>Does the patient have a</li></ol>	diagnosis of chronic granulomatous	Υ	N

Reference Number: C6638-A/ Effective Date: 02/22/2017

disease (CGD)? [If no, skip to question 6.] 3. Has this plan authorized this medication in the past for this Υ Ν patient (i.e., previous authorization is on file under this plan)? [If no, skip to question 5.] 4. Has the patient demonstrated an overall reduction in the Υ Ν incidence and/or severity of serious infections since starting Actimmune? [No further questions.] 5. Is the patient also receiving prophylactic antimicrobials (such Υ Ν as itraconazole and trimethoprim/sulfamethoxazole)? [If yes, skip to question 9.] [If no, no further questions.] Ν 6. Does the patient have a diagnosis of severe, malignant Υ osteopetrosis? [If no, no further questions.] Ν 7. Has this plan authorized this medication in the past for this Υ patient (i.e., previous authorization is on file under this plan)? [If no, skip to question 10.] 8. Is the patient responding to therapy as demonstrated by Υ Ν having no disease progression? [No further questions.] 9. Is the patient at least 1 year old? Υ Ν

Reference Number: C6638-A/ Effective Date: 02/22/2017

[If no, no further questions.]

Prescriber (Or Authorized) Signature	Date	
I affirm that the information given on this form is true and accurate as of	this date.	
Comments:		
List specialty:		
appropriate specialist based on the condition being treated?	Y IN	

Reference Number: C6638-A/ Effective Date: 02/22/2017